The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
 
Giampaolo Bianchini
Honoraria - AstraZeneca/Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Giulia Viale
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Lilly; Pfizer
 
Matteo Dugo
Travel, Accommodations, Expenses - Oncocyte Corp.
 
Chiun-Sheng Huang
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiich Sankyo; EirGenix; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Daiich Sankyo; Lilly; Novartis; Roche
Research Funding - Aston Sci (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - EirGenix; Gilead Sciences (Inst); Pfizer (Inst); Roche
 
Daniel Egle
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Menarini Group; Novartis; Pfizer; Roche/Genentech; Sirius Medical
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Roche/Genentech
Research Funding - Sirius Medical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Menarini Group; Pfizer
 
Maurizio Callari
No Relationships to Disclose
 
Hamid Ali
No Relationships to Disclose
 
Begoña Bermejo
Consulting or Advisory Role - AstraZeneca Spain; Lilly; Menarini; Novartis
Speakers' Bureau - Daiichi Sankyo; Genentech; MSD; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer
 
Claudio Zamagni
Consulting or Advisory Role - AstraZeneca; Celgene; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Morphotek (Inst); MSD Oncology (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; MSD Oncology; Novartis; Pfizer; Roche
 
Xiao Qian Wang
No Relationships to Disclose
 
Marc Thill
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Celgene; Genomic Health; Hexal; Medtronic; Novartis; Pfizer; pfm medical; Roche; RTI Health Solutions
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Biom'up; Celgene; Eisai; Genomic Health; Lilly; MSD Oncology; NeoDynamics; Norgine; Novartis; Pfizer; pfm medical; Roche; RTI Health Solutions; Tesaro
Research Funding - Genomic Health International
Travel, Accommodations, Expenses - Amgen; AstraZeneca/Daiichi Sankyo; Biom'up; Celgene; Eisai; Genomic Health; Hexal; Lilly; Medtronic; NeoDynamics; Norgine; Novartis; Pfizer; pfm medical; Roche/Genentech; RTI Health Solutions; Tesaro
Other Relationship - Amgen; Celgene; Lilly
 
Antonio Anton
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Gilead Sciences; Lilly
Speakers' Bureau - AstraZeneca Spain; Daiichi Sankyo/Lilly; Lilly; Novartis; Pfizer; Roche
 
Stefania Russo
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Lilly; Novartis
 
Eva Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Menarini Group; MSD Oncology; Novartis; Novartis; Pfizer; Reveal Genomics; Reveal Genomics; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Roche
Research Funding - Pfizer; Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Vladimir Semiglazov
No Relationships to Disclose
 
Marco Colleoni
No Relationships to Disclose
 
Lucia Del Mastro
Honoraria - Gilead Sciences; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; Menarini; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Roche
 
Giuseppe Viale
Honoraria - AstraZeneca/Daiichi Sankyo; Gilead/Forty Seven; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; DAKO; Menarini; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo
 
Luca Gianni
Consulting or Advisory Role - AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; Denali Therapeutics; Menarini; Revolution Medicines; Roche; Synaffix; Zymeworks
Patents, Royalties, Other Intellectual Property - Roche